Flexion Therapeutics names first chief business officer

Arthur Fratamico takes up the role

Arthur Fratamico has joined US drug developer Flexion Therapeutics as its first chief business officer. He has more than 13 years of business development experience with emerging biopharmaceutical companies.

Prior to joining Flexion, Fratamico led the business development efforts for Trevena, Gemin X Pharmaceuticals and MGI Pharma.

Flexion is a developer of therapeutics for musculoskeletal disorders. The firm is currently advancing a portfolio of drug candidates that have the potential to treat osteoarthritis.

You may also like

Research & Development

Flexion Therapeutics signs agreements with four pharmaceutical firms

Flexion Therapeutics, a US developer of drug candidates, has signed agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and has gained funding from Pfizer.
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Subscribe now